Want to see KR:067630 full AI Analyst Report?
HLB Life Science Co.,Ltd. (067630) AI Stock Analysis
HLB Life Science Co.,Ltd.
(Korea Exchange:067630)
The score is primarily held back by weak financial performance driven by sharp revenue contraction, recurring losses, and sustained negative operating/free cash flow. Technicals are mixed with neutral momentum overall and some near-term oversold readings, providing only limited support. Valuation adds uncertainty because the negative P/E is loss-driven and dividend yield data is unavailable.
HLB Life Science Co.,Ltd. (067630) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 401.49B
- Dividend Yield
- ―
- Average Volume (3M)
- 577.66K
- Price to Earnings (P/E)
- -32.2
- Beta (1Y)
- 0.43
- Revenue Growth
- -42.14%
- EPS Growth
- 52.55%
- Country
- KR
- Employees
- ―
- Sector
- General
- Sector Strength
- 55
- Industry
- Renewable Utilities
HLB Life Science Co.,Ltd. Business Overview & Revenue Model
Company Description
HLB Life Science Co Ltd specializes in a range of energy solutions, encompassing both traditional services and renewable power initiatives. Its offerings include advanced energy-saving facilities, systems for recovering condensing water, combined hea...
HLB Life Science Co.,Ltd. Financial Statement Overview
Summary
Overall financial quality is weak: revenue fell sharply in 2025 (~44% YoY) and results swung back to a very large loss after a brief 2024 profit. Cash generation is a major risk with negative operating and free cash flow across 2023–2025, implying continued funding needs. The balance sheet offers some support via a meaningful equity base, but leverage worsened (debt-to-equity ~0.31 to ~0.54) and returns on equity are negative.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.79B | 45.75B | 102.24B | 97.99B | 99.59B | 53.49B |
| Gross Profit | -494.41M | -494.41M | -2.19B | -748.57M | -3.05B | -5.54B |
| EBITDA | -83.58B | -83.58B | 25.87B | 22.84B | -45.75B | -49.88B |
| Net Income | -99.79B | -99.79B | 6.14B | -5.98B | -54.36B | -49.29B |
Balance Sheet | ||||||
| Total Assets | 478.09B | 478.09B | 539.02B | 423.50B | 411.79B | 270.80B |
| Cash, Cash Equivalents and Short-Term Investments | 13.88B | 13.88B | 79.57B | 78.86B | 131.44B | 139.96B |
| Total Debt | 160.36B | 160.36B | 123.78B | 166.58B | 147.47B | 4.62B |
| Total Liabilities | 180.35B | 180.35B | 140.19B | 192.29B | 175.72B | 24.19B |
| Stockholders Equity | 297.35B | 297.35B | 398.34B | 230.80B | 234.72B | 246.19B |
Cash Flow | ||||||
| Free Cash Flow | -48.88B | -48.88B | -59.47B | -31.54B | -41.40B | -16.69B |
| Operating Cash Flow | -22.93B | -22.93B | -32.01B | -10.02B | -29.74B | -14.08B |
| Investing Cash Flow | -34.63B | -34.63B | -37.78B | -8.88B | -72.64B | 8.82B |
| Financing Cash Flow | 18.26B | 18.26B | 105.74B | 4.79B | 102.10B | -641.09M |
HLB Life Science Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:067630, the sentiment is Neutral. The current price of 3525.00 is below the 20-day moving average (MA) of 3733.50, above the 50-day MA of 3164.70, and above the 200-day MA of 3470.01, indicating a neutral trend. The MACD of 32.93 indicates Positive momentum. The RSI at 45.91 is Neutral, neither overbought nor oversold. The STOCH value of 10.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KR:067630.
HLB Life Science Co.,Ltd. Peers Comparison
Overall Rating
- KR:06763044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:067630 | 44Neutral | KRW 401.49B | -32.21 | ― | ― | -42.14% | 52.55% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:067630 | HLB Life Science Co.,Ltd. | 3295.00 | -710.00 | -17.73% | |
| KR:047920 | HLB PHARMACEUTICAL CO., LTD. | 9500.00 | -4092.49 | -30.11% | |
| KR:102940 | Kolon Life Science Inc. | 12410.00 | -20340.00 | -62.11% | |
| KR:206650 | EuBiologics Co., Ltd. | 7730.00 | -4550.00 | -37.05% | |
| KR:215600 | SillaJen, Inc. | 2020.00 | -815.00 | -28.75% | |
| KR:493280 | IMBiologics Corp. | 13160.00 | -90840.00 | -87.35% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026